Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.72 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423998 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477862 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1ARAKR1B10AKR1B1 | |
| SCHEMBL14397354 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL950693 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477867 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL5907001 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL13844000 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL28559933 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1ARAKR1B10AKR1B1 | |
| SCHEMBL950691 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14360068 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1ARAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994022900-A1 | AZA-ANDROSTANE-17β-CARBOXAMIDES | CIBA-GEIGY AG (CH) | 1994-10-13 | — | — | WO | disclosed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |